Immunology for Non-Immunologists: Hot vs. Cold Tumors

Hot, cold, and in-between. Tumors come in all forms — some better targets for immunotherapy treatment than others. This post will help you learn more about hot tumors, cold tumors, and what researchers are doing to make cold tumors more receptive to immunotherapies.  What Are Hot Tumors?  Tumors described as “hot” are those that show […]

Useful Tools in Immunology: OMIM.org

The Online Mendelian Inheritance in ManⓇ website, or OMIMⓇ, is a publicly available catalog of over 15,000 human genes and all known genetic disorders updated daily by the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University. Intended for physician and research use, OMIM is a searchable index of clinical features, phenotypes, genes, and more. […]

The Yolk Sac Found to be a Second Origin of Endothelial Cells

A recent paper published in Nature, A dual origin for blood vessels, describes experiments that trace the development of endothelial cells in mice. By targeting expression of a fluorescent protein to cells of the yolk sac, Plein et al. were able to show that endothelial cells lining blood vessels develop from two different embryonic cell […]

Useful Tools in Immunology: The Immune Epitope Database

The Immune Epitope Database (IEDB) is a free online resource established by the National Institute for Health. The IEDB makes it easy for scientists and researchers to search for experimental data characterizing antibody and T cell epitopes for allergens, infectious diseases, autoimmune diseases, and transplants/alloantigens. Beyond epitope search, the IEDB also offers unique epitope analysis […]

Global Cancer Biomarkers Market to Exceed $157B by 2022

The Global Cancer Biomarkers Market is expected to exceed $157.37 Billion by 2022 at a compound annual growth rate (CAGR) of 13.3%, fueled by increasing incidences of cancer worldwide and emerging technologies, according to a report. Cancer biomarkers are used to indicate the biological state of a tumor and to more accurately diagnose, treat, and […]

Immune Cell Quality: The Key to Personalized Medicine (Podcast)

Breakthroughs in personalized medicine start with high-quality, well-characterized immune cell products. Making such products widely available to researchers in fields like immunology, inflammation, and vaccine development was the catalyst to founding Astarte Biologics over 14 years ago. Since recognizing a need in the industry and launching our company with human PBMC and T cells, we’ve […]

How Biotech Is Fighting These 5 Deadly Diseases

Biotech researchers have made some of the most phenomenal discoveries and advancements in human medicine over the past half-century, from breakthrough medications for infectious and viral diseases to sequencing the human genome to innovative immunotherapy treatments for cancer. Here is a look at how biotech is fighting five of the most problematic diseases on the […]

Gene Therapy News: FDA Approves First In Vivo Treatment

In 2017, we witnessed gene therapy breakthroughs up to the very end. In the final weeks of the year, the first in vivo gene therapy, Luxturna, was approved by the FDA. Luxturna is intended to improve sight for patients with rare forms of inherited vision loss. Luxturna is administered through a one-time injection into a […]

Anti-SIRPα Antibodies: A Promising Avenue for Immunotherapy

Conventional cancer therapies such as chemotherapy and radiation have a significant downfall: while targeting cancerous tumors, they also damage healthy cells which can lead to undesirable patient side-effects. Despite high expectations at the onset, treatments using monoclonal antibodies have historically faced limitations. While attempting to discover why monoclonal antibodies were not performing as expected, researchers […]

Thank You for a Great 2017!

It’s hard to believe 2017 is coming to a close in just a few short days. What a year it has been! There have been many groundbreaking immunotherapy innovations this year. From the first-ever FDA-approved CAR-T cell therapy to the federal PACT initiative investing $215 million in immunotherapy research to countless other advancements, it’s incredible […]